好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Tracking Cortical Changes Throughout Cognitive Decline in Parkinson’s Disease: A Longitudinal MRI Study
Movement Disorders
P5 - Poster Session 5 (5:30 PM-6:30 PM)
10-016
To investigate longitudinal cortical thinning (CT) in Parkinson’s disease patients with normal cognition (PD-CN), with stable mild cognitive impairment (PD-MCIs), and in patients who convert to MCI (PD-MCIc) and dementia (PD-Dc).
Identification of biomarkers underlying cognitive decline in PD may facilitate the identification of patients at risk of dementia.
We recruited 114 patients with known cognitive outcome after 4 years of follow-up (37 PD-CN, 21 PD-MCIs, 36 PD-MCIc, 21 PD-Dc) and 39 healthy controls (HC), all age/sex-matched. Patients underwent 4 visits, including neuropsychological/clinical assessments and MRI scans. Baseline CT was compared between patients and HC. In PD, CT progression overtime was investigated within and between groups.
At baseline, compared to HC and PD-CN patients, PD-Dc, PD-MCIc and PD-MCIs patients showed greater cortical damage in the whole parietal lobe, with additional involvement of temporal cortex in PD-Dc. Overtime, PD-CN and PD-MCIc patients accumulated the most damage in frontal and parietal regions. PD-MCIs and PD-Dc patients showed similar patterns of thinning in the left temporal and parietal lobes, with involvement of the right side in PD-Dc. The posterior cingulate cortex (PCC) and supramarginal gyrus were affected overtime only in the ‘converter’ groups. TimeXgroup interaction showed that (vs the other patient groups): PD-Dc and PD-CN cases accumulated the least damage; PD-MCIc patients had specific CT accumulation in PCC, supramarginal and parahypocampal gyri; PD-MCIs patients showed a widespread pattern of damage in fronto-temporo-parietal regions.
CT progression is more prominent in the initial stages of PD cognitive decline. The involvement of specific temporo-parietal regions is associated with the conversion to a more severe stage of cognitive impairment. In PD, CT of crucial brain regions may be a powerful marker for the identification of patients at risk of developing dementia. 
Authors/Disclosures
Elisa Canu (Ospedale San Raffaele)
PRESENTER 		The institution of Elisa Canu has received research support from Italian Ministry of Health .
Federica Agosta (San Raffaele Scientific Institute) Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC.
No disclosure on file
Silvia Basaia Silvia Basaia has nothing to disclose.
Iva Stankovic (Neurology Clinic, Clinical Center of Serbia, University of Belgrade) Iva Stankovic has nothing to disclose.
No disclosure on file
No disclosure on file
Elka Stefanova No disclosure on file
Vladimir S. Kostic, MD, PhD (Institute of Neurology CCS) Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche. An immediate family member of Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Alkaloid. The institution of Dr. Kostic has received research support from Ministry of 好色先生, Science and Technological Development of Serbia.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.